Opelconazole (PC945)
Invasive Pulmonary Aspergillosis (refractory to standard care)
Phase 3Active
Key Facts
Indication
Invasive Pulmonary Aspergillosis (refractory to standard care)
Phase
Phase 3
Status
Active
Company
About Pulmocide
Pulmocide is a clinical-stage biotech advancing inhaled therapies for severe respiratory fungal infections. Its lead asset, opelconazole, is a potent inhaled antifungal in a pivotal Phase 3 trial for invasive pulmonary aspergillosis in patients failing standard care, supported by FDA Fast Track and QIDP designations. The company leverages a specialized team with deep expertise in inhaled drug discovery and development. Backed by top-tier investors, Pulmocide is positioned to address a significant unmet need in a high-mortality disease area with a targeted therapeutic approach.
View full company profile